Livagen — EU research guide.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series targeting liver cell chromatin and gene expression, proposed to support hepatic function. It is the synthetic counterpart to Ovagen, a natural liver-tissue complex bioregulator in the same research family.
What is Livagen?
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series targeting liver cell chromatin and gene expression, proposed to support hepatic function. It is the synthetic counterpart to Ovagen, a natural liver-tissue complex bioregulator in the same research family.
What does the research show?
Research is limited to hepatocyte gene-expression studies and small animal cohorts from Eastern European groups. No independently replicated human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Livagen is not yet in our price comparison
We expand EU supplier coverage every month.